NovoCure Limited

NovoCure Limited

10.53
EUR
-0.02
(-0.19%)
-0.94EPS
Feb 25Next Earn

Important Dates

NovoCure Ltd.'s next confirmed earnings release is scheduled for February 25, 2027.

Earnings Date2/25/2027

Share Statistics

As of September 30, 2026, NovoCure Ltd. has 116.91M shares outstanding.

Shares Outstanding116.91M

Financial Position

As of September 30, 2026, NovoCure Ltd. maintains a current ratio of 2.49, meaning it holds 2.5x the short-term assets needed to cover near-term liabilities.

Current Ratio2.49
Quick Ratio2.30
Debt / Equity66.04
Debt / EBITDA-2.15

Financial Efficiency

EUR

Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a negative return on equity (ROE) of -35.18, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -11.12, reflecting losses generated across the asset base. The company generates approximately 398,760.02 in revenue per employee across its workforce of 1,605.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.18 indicates how many times NovoCure Ltd. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-35.18
Return on Assets (ROA)-11.12
Revenue Per Employee398,760.02
Employee Count1,605.00
Inventory Turnover4.18

Taxes

EUR

Over the twelve months ended September 30, 2026, NovoCure Ltd. recorded an income tax benefit of -7.78M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -115.18M and -107.40M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax-7.78M

Income Statement

EUR

Over the twelve months ended September 30, 2026, NovoCure Ltd. generated 640.01M in revenue and converted that into -107.40M in net income, yielding earnings per share of -0.94. EBITDA reached -94.83M, while operating income came in at -109.89M.

Revenue640.01M
Gross Profit492.91M
Operating Income-109.89M
Pretax Income-115.18M
Net Income-107.40M
EBITDA-94.83M
EBIT-109.89M
Earnings Per Share (EPS)-0.94

Balance Sheet

EUR

As of September 30, 2026, NovoCure Ltd. holds 408.93M in cash and equivalents against 204.30M in total debt, resulting in a net debt position of 87.88M. Total book value stands at 309.35M, with working capital of 355.44M providing operational flexibility.

Cash & Cash Equivalents408.93M
Total Debt204.30M
Net Debt87.88M
Equity (Book Value)309.35M
Book Value Per Share2.65
Working Capital355.44M

Cash Flow

EUR

NovoCure Ltd. produced -637,020.60 in operating cash flow over the twelve months ended September 30, 2026. After subtracting -21.07M in capital expenditures, free cash flow totaled -21.71M - equivalent to -0.19 per share.

Operating Cash Flow-637,020.60
Capital Expenditures-21.07M
Free Cash Flow-21.71M
FCF Per Share-0.19

Margins

Over the twelve months ended September 30, 2026, NovoCure Ltd. posted a gross margin of 77.02, reflecting its pricing power and cost economics. The operating margin of -17.17 and net profit margin of -16.78 provide insight into operational efficiency.

Gross Margin77.02
Operating Margin-17.17
Pretax Margin-18.00
Profit Margin-16.78
EBITDA Margin-14.82